DOCSLIB.ORG

Dementia and Antipsychotic Treatment: Literature Search Strategies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dementia and Antipsychotic Treatment: Literature Search Strategies Dementia and Antipsychotic Treatment: Literature Search Strategies Use of second generation antipsychotic agents for off-label uses including dementia These searches were conducted on 02/03/13 and were an extension of the search strategy used for the AHRQ review of Maglione et al. (2011). MEDLINE (PubMed) #1 Search atypical antipsychotic* OR atypical anti-psychotic* OR "risperidone"[MeSH 17550 Terms]OR "paliperidone palmitate"[Supplementary Concept] OR "asenapine"[Supplementary Concept] OR "iloperidone"[Supplementary Concept] OR "risperidone"[Supplementary Concept] OR "ziprasidone"[Supplementary Concept] OR "olanzapine"[Supplementary Concept] OR "quetiapine"[Supplementary Concept] OR "aripiprazole"[Supplementary Concept] OR olanzapine[tiab] OR quetiapine[tiab] OR risperidone[tiab] OR ziprasidone[tiab] OR aripiprazole[tiab] OR paliperidone[tiab] OR iloperidone[tiab] OR asenapine[tiab] #2 Search "Antipsychotic Agents"[MeSH] OR "Antipsychotic Agents"[Pharmacological 118317 Action] #3 Search "Sleep Initiation and Maintenance Disorders"[Mesh] OR insomni*[tiab] OR 932761 sleep*[tiab] OR "Anorexia Nervosa"[Mesh] OR "Anorexia"[Mesh] OR "Bulimia"[Mesh] OR "Bulimia Nervosa"[Mesh] OR anorexi*[tiab] OR bulimi*[tiab] OR substance abuse* OR drug abuse* OR alcohol abuse OR addict* OR drug dependen* OR cocaine OR heroin OR "Substance-Related Disorders"[Mesh] OR "Anxiety"[Mesh] OR "Anxiety Disorders"[Mesh] OR "Anti-Anxiety Agents"[Mesh] OR "Anti-Anxiety Agents "[Pharmacological Action] OR anxiety[tiab] OR anxious*[tiab] OR anti-anxiety[tiab] OR antianxiety[tiab] OR autism [tiab] OR autistic[tiab] OR "Attention Deficit Disorder with Hyperactivity"[Mesh] OR attention deficit disorder[tiab] OR adhd [tiab] OR "Tourette Syndrome"[Mesh] OR tourette*[tiab] OR "Obsessive-Compulsive Disorder"[Mesh] OR "Obsessive Behavior"[Mesh] OR "Stress Disorders, Post-Traumatic"[Mesh] OR "Personality Disorders"[Mesh] OR "Dementia"[Mesh] OR "Depressive Disorder, Major"[Mesh] OR obsessive*[tiab] OR posttraumatic stress[tiab] OR post-traumatic stress[tiab] OR post traumatic stress[tiab] OR ptsd[tiab] OR personality disorder*[tiab] OR dementia[tiab] OR major depress*[tiab] #4 Search "off-label" [tiab] OR "off label" [tiab] OR "offlabel" [tiab] 2874 #5 Search (#1 OR #2) AND (#3 OR #4) 27141 #6 Search ((animal*[tiab] OR "animals"[MeSH Terms]) NOT (human[tiab] OR humans[tiab] 3636066 OR "humans"[MeSH Terms])) #7 Search (#5) NOT #6 22076 #8 Search english[Language] 18108524 #9 Search (#7) AND #8 18687 #10 Search ("2010/09/01"[Date - Publication] : "2013/02/01"[Date - Publication]) 2240450 #11 Search (#9) AND #10 1624 PsycInfo S1 olanzapine OR quetiapine OR risperidone OR ziprasidone OR aripiprazole OR 10,413 paliperidone OR iloperidone OR asenapine S2 (atypical antipsychotic* OR atypical anti-psychotic*) 5,773 S3 (depression OR depressive OR anxiety OR anti-anxiety OR antianxiety OR 552,744 insomnia OR sleep* OR anorexi* OR bulimi* OR tourett* OR attention deficit disorder OR adhd OR substance abuse* OR drug abuse* OR alcohol abuse OR addict* OR drug dependen* OR cocaine OR heroin OR personality disorder* OR posttraumatic stress disorder OR post-traumatic stress OR ptsd or dementia OR "major depressive" OR obsessive-compulsive OR obsessive compulsive or dementia OR ((geriatric OR elderly) AND (agitation OR agitated))) S4 KW (off-label OR "off label" OR offlabel OR pharmacoepidemiolog*) OR TI (off- 168 label OR "off label" OR offlabel OR pharmacoepidemiolog*) S5 S1 OR S2 12,864 S6 S3 OR S4 548,086 S7 S5 AND S6 4,131 S8 LA english 3,126,642 S9 S7 AND S8 3,849 S10 S9 Limiters - Published Date from: 20100901-20130231 657 Cochrane Library #1 olanzapine: ti,ab, kw or quetiapine: ti,ab, kw or risperidone: ti,ab, kw or 3631 ziprasidone: ti,ab, kw or aripiprazole: ti,ab, kw #2 asenapine: ti,ab, kw or iloperidone: ti,ab, kw or paliperidone: ti,ab, kw 107 #3 #1 or #2 3697 #4 "schizophrenia": ti,ab, kw or "bipolar disorder": ti,ab, kw 9459 #5 #3 not #5 1496 Limited to Systematic Reviews and Controlled Trials 1457 Use of antipsychotic agents for patients with dementia These searches were conducted on in January 2015 and were designed to encompass all possible literature that addressed the use of antipsychotic agents in individuals with dementia, including literature already covered by the prior search and the searches used in the AHRQ review on use of atypical antipsychotic agents for off-label indications.
Load more

Recommended publications
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update
    PAIN MANAGEMENT/CONCEPTS Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update Steven M. Green, MD, Mark G. Roback, MD, Robert M. Kennedy, MD, Baruch Krauss, MD, EdM From the Department of Emergency Medicine, Loma Linda University Medical Center and Children’s Hospital, Loma Linda, CA (Green); the Department of Pediatrics, University of Minnesota, Minneapolis, MN (Roback); the Division of Emergency Medicine, St. Louis Children’s Hospital, Washington University, St. Louis, MO (Kennedy); and the Division of Emergency Medicine, Children’s Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, MA (Krauss). We update an evidence-based clinical practice guideline for the administration of the dissociative agent ketamine for emergency department procedural sedation and analgesia. Substantial new research warrants revision of the widely disseminated 2004 guideline, particularly with respect to contraindications, age recommendations, potential neurotoxicity, and the role of coadministered anticholinergics and benzodiazepines. We critically discuss indications, contraindications, personnel requirements, monitoring, dosing, coadministered medications, recovery issues, and future research questions for ketamine dissociative sedation. [Ann Emerg Med. 2011;xx:xxx.] 0196-0644/$-see front matter Copyright © 2011 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2010.11.030 INTRODUCTION thalamocortical and limbic systems, effectively dissociating the The dissociative
    [Show full text]
  • Bifeprunox: a Novel Antipsychotic Agent with Partial Agonist Properties at Dopamine D2 and Serotonin 5-HT1A Receptors
    DRUG EVALUATION Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors Marie-Louise G Most second-generation, atypical, dopamine (DA) D2/5-HT2 blocking antipsychotics still Wadenberg induce extrapyramidal side effects (EPS) in higher doses. Weight gain and metabolic University of Kalmar, disturbances are also a problem, and negative and cognitive symptoms have not been Department of Natural Sciences, Norra Vagen 49, sufficiently addressed. The current brain DA mesolimbic hyperactive/mesocortical SE-391 82 Kalmar, Sweden hypoactive hypothesis of schizophrenia suggests that DA D2/5-HT1A receptor partial agonist Tel.: +46 480 446 277; properties may be more efficacious with less side effects. DA D2 receptor partial agonists Fax: +46 480 446 244; may stabilize a hyperactive/hypoactive DA condition. Additional 5-HT stimulation may marie-louise.wadenberg@ 1A hik.se enhance therapeutic efficacy and also improve EPS liability profile. In clinical trials in schizophrenic patients, the novel DA D2/5-HT1A partial agonist bifeprunox indeed demonstrates therapeutic efficacy, a safe EPS profile and appears beneficial regarding weight gain, prolactin, blood lipid and glucose levels and cardiac rhythm. The data on bifeprunox are promising and suggest that combined DA D2/5-HT1A partial agonism may well be important properties for future-generation antipsychotics. Bifeprunox, a novel antipsychotic agent with a (DA D1, D2, D4, 5-HT2A/C, 5-HT1A, hista- so-called third-generation atypical pharmacolog- mine H1, α1, α2, cholinergic muscarinic recep- ical profile, is currently in clinical trials and tor affinity) and comparatively lower affinity for expected to launch as a schizophrenia therapy in the DA D2 receptor than traditional APDs.
    [Show full text]
  • HTR1A Polymorphisms and Clinical Efficacy Of
    International Journal of Neuropsychopharmacology, (2016) 19(5): 1–10 doi:10.1093/ijnp/pyv125 Advance Access publication November 14, 2015 Research Article research article HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis Yoshiteru Takekita, MD, PhD; Chiara Fabbri, MD; Masaki Kato, MD, PhD; Yosuke Koshikawa, MA; Aran Tajika, MD; Toshihiko Kinoshita, MD, PhD; Alessandro Serretti, MD, PhD Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Drs Takekita, Fabbri, and Serretti); Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan (Drs Takekita, Kato, Koshikawa, and Kinoshita); Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan (Dr Tajika). Correspondence: Yoshiteru Takekita, MD, PhD, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy ([email protected]). Abstract Background: This meta-analysis was conducted to evaluate whether HTR1A gene polymorphisms impact the efficacy of antipsychotic drugs in patients with schizophrenia. Methods: Candidate gene studies that were published in English up to August 6, 2015 were identified by a literature search of PubMed, Web of Science, and Google scholar. Data were pooled from individual clinical trials considering overall symptoms, positive symptoms and negative symptoms, and standard mean differences were calculated by applying a random-effects model. Results: The present meta-analysis included a total of 1281 patients from 10 studies. Three polymorphisms of HTR1A (rs6295, rs878567, and rs1423691) were selected for the analysis. In the pooled data from all studies, none of these HTR1A polymorphisms correlated significantly with either overall symptoms or positive symptoms.
    [Show full text]
  • Antiemetics/Antivertigo Agents
    Antiemetic Agents Therapeutic Class Review (TCR) May 1, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. May 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2019 Magellan Rx Management. All Rights Reserved. 3 FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) NK1 receptor antagonists aprepitant capsules generic, Merck In combination with other antiemetic agents for: (Emend®)1 .
    [Show full text]
  • New Therapeutic Property of Dimebon As a Neuroprotective Agent
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2016, 23, 1-12 1 REVIEW ARTICLE New Therapeutic Property of Dimebon as a Neuroprotective Agent Aleksey Ustyugov1, Elena Shevtsova1, George E. Barreto2,3, Ghulam Md Ashraf 4, Sergey O. Bachurin1 and Gjumrakch Aliev1,5,6,* 1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severniy Proezd 1, Cher- nogolovka, 142432, Russia; 2Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Uni- versidad Javeriana, Bogotá D.C., Colombia; 3Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 4King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Ara- bia; 5GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San An- tonio, TX, 78229, USA; 6School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA Abstract: Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of “old” agents with prominent neuroprotective effects. In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain’s pathological processes using in vivo protei- A R T I C L E H I S T O R Y nopathy models. In the study, neurodegenerative pathology has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which Received: March 13, 2016 Revised: June 08, 2016 are involved in a number of neurological disorders. We have also presented our in vitro Accepted: July 24, 2016 model based on overexpression of an aberrant mutant form of transactive response DNA DOI: 10.2174/0929867323666160804 binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.
    [Show full text]
  • Modafinil/Armodafinil (Provigil ® /Nuvigil
    Drug and Biologic Coverage Policy Effective Date ............................................ 7/1/2020 Next Review Date… ..................................... 7/1/2021 Coverage Policy Number .................................. 1501 Modafinil / Armodafinil for Individual and Family Plans Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Obstructive Sleep Apnea Treatment Services FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 3 General Background ............................................ 3 Coding/ Billing Information ................................... 6 References .......................................................... 6 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies
    [Show full text]
  • Amphetamine/Dextroamphetamine IR Generic
    GEORGIA MEDICAID FEE-FOR-SERVICE STIMULANT AND RELATED AGENTS PA SUMMARY Preferred Non-Preferred Amphetamine/dextroamphetamine IR generic Adzenys ER (amphetamine ER oral suspension) Armodafinil generic Adzenys XR (amphetamine ER dispersible tab) Atomoxetine generic Amphetamine/dextroamphetamine ER (generic Concerta (methylphenidate ER/SA) Adderall XR) Dextroamphetamine IR tablets generic Aptensio XR (methylphenidate ER) Focalin (dexmethylphenidate) Clonidine ER generic Focalin XR (dexmethylphenidate ER) Cotempla XR (methylphenidate ER disintegrating Guanfacine ER generic tablet) Methylin oral solution (methylphenidate) Daytrana (methylphenidate TD patch) Methylphenidate CD/CR/ER generic by Lannett Desoxyn (methamphetamine) [NDCs 00527-####-##] and Kremers Urban [NDCs Dexmethylphenidate IR generic 62175-####-##] (generic Metadate CD) Dexmethylphenidate ER generic Methylphenidate IR generic Dextroamphetamine ER capsules generic Modafinil generic Dextroamphetamine oral solution generic Quillichew ER (methylphenidate ER chew tabs) Dyanavel XR (amphetamine ER oral suspension) Quillivant XR (methylphenidate ER oral suspension) Evekeo (amphetamine tablets) Vyvanse (lisdexamfetamine) Methamphetamine generic Zenzedi 5 mg, 10 mg IR tablets (dextroamphetamine) Methylphenidate IR chewable tablets generic Methylphenidate ER/SA (generic Concerta) Methylphenidate ER/LA/SR (generic Ritalin LA, Ritalin SR, Metadate ER) Methylphenidate ER/SA 72 mg generic Methylphenidate oral solution generic Mydayis (amphetamine/dextroamphetamine ER) Ritalin LA 10 mg
    [Show full text]
  • MEDICATION GUIDE Armodafinil Tablets, C-IV Read the Medication Guide That Comes with Armodafinil Before You Start Taking It and Each Time You Get a Refill
    MEDICATION GUIDE Armodafinil Tablets, C-IV Read the Medication Guide that comes with armodafinil before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your condition or treatment. What is the most important information I should know about armodafinil? Armodafinil may cause serious side effects including a serious rash or a serious allergic reaction that may affect parts of your body such as your liver or blood cells. Any of these may need to be treated in a hospital and may be life-threatening. Stop taking armodafinil and call your doctor right away or get emergency help if you have any of these symptoms: • skin rash, hives, sores in your mouth, or your skin blisters and peels • swelling of your face, eyes, lips, tongue, or throat • trouble swallowing or breathing • fever, shortness of breath, swelling of the legs, yellowing of the skin or whites of the eyes, or dark urine. If you have a severe rash with armodafinil, stopping the medicine may not keep the rash from becoming life- threatening or causing you to be permanently disabled or disfigured. Armodafinil is not approved for use in children for any medical condition. It is not known if armodafinil is safe or if it works in children under the age of 17. What is armodafinil? Armodafinil is a prescription medicine used to improve wakefulness in adults who are very sleepy due to one of the following diagnosed sleep disorders: • narcolepsy • obstructive sleep apnea (OSA).
    [Show full text]
  • Award-Winning Hong Kong Film Gallants to Premiere at Hong Kong
    FOR IMMEDIATE RELEASE Award-winning Hong Kong film Gallants to premiere at Hong Kong Film Festival 2011 in Singapore One-week festival to feature a total of 10 titles including four new and four iconic 1990s Hong Kong films of action and romance comedy genres Singapore, 30 June 2011 – Movie-goers can look forward to a retro spin at the upcoming Hong Kong Film Festival 2011 (HKFF 2011) to be held from 14 to 20 July 2011 at Cathay Cineleisure Orchard. A winner of multiple awards at the Hong Kong Film Awards 2011, Gallants, will premiere at HKFF 2011. The action comedy film will take the audience down the memory lane of classic kung fu movies. Other new Hong Kong films to premiere at the festival include action drama Rebellion, youthful romance Breakup Club and Give Love. They are joined by retrospective titles - Swordsman II, Once Upon A Time in China II, A Chinese Odyssey: Pandora’s Box and All’s Well, Ends Well. Adding variety to the lineup is Quattro Hong Kong I and II, comprising a total of eight short films by renowned Hong Kong and Asian filmmakers commissioned by Brand Hong Kong and produced by the Hong Kong International Film Festival Society. The retrospective titles were selected in a voting exercise that took place via Facebook and SMS in May. Public were asked to select from a list of iconic 1990s Hong Kong films that they would like to catch on the big screen again. The list was nominated by three invited panelists, namely Randy Ang, local filmmaker; Wayne Lim, film reviewer for UW magazine; and Kenneth Kong, film reviewer for Radio 100.3.
    [Show full text]
  • Neurotransmitters-Sample-Report
    Neurotransmitters Test the messengers of your neural network 1(866) 364-0963 www.vibrant-wellness.com 1360 Bayport Ave. Ste. B [email protected] San Carlos, CA 94070 Neurotransmitters Vibrant Wellness | 1360 Bayport Ave, Ste B. San Carlos, CA 94070 1(866) 364-0963 | [email protected] | www. vibrant-wellness.com Final Report Date: 06-19-2020 16:03 Specimen Collected: 06-18-2020 16:03 Accession ID: 2006190275 Specimen Received: 06-19-2020 10:03 LAST NAME FIRST NAME GENDER DATE OF BIRTH ACCESSION ID DATE OF SERVICE PATIENT TEST2 MALE 1998-01-06 2006190275 06-18-2020 16:03 PATIENT PROVIDER Name: TEST2 PATIENT Practice Name: Vibrant IT4 Practice Date of Birth: 1998-01-06 Provider Name: Demo Client, DDD (999994) Gender: Male Street Address: TEST STREET Age: 22 City: TEST CITY State: KY Fasting: FASTING Zip #: 42437 Telephone #: Fax #: 000-000-0000 Vibrant Wellness is pleased to present to you, 'Neurotransmitters', to help you make healthy lifestyle, dietary and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being. The Vibrant Neurotransmitters is a test to measure inhibitory, excitatory and other neurotransmitters . The panel is designed to give a complete picture of an individual’s levels of neurotransmitters in urine. Interpretation of Report: The report contains the complete list of the all urine neurotransmitters tested with quantitative results to enable a full overview along with the corresponding reference ranges. The classification of Red indicates a result that is outside the reference range and the classification of Green denotes a result that is within the reference range.
    [Show full text]
  • The Role of Kinetic Context in Apparent Biased Agonism at Gpcrs
    ARTICLE Received 2 Jul 2015 | Accepted 27 Jan 2016 | Published 24 Feb 2016 DOI: 10.1038/ncomms10842 OPEN The role of kinetic context in apparent biased agonism at GPCRs Carmen Klein Herenbrink1, David A. Sykes2, Prashant Donthamsetti3,4, Meritxell Canals1, Thomas Coudrat1, Jeremy Shonberg5, Peter J. Scammells5, Ben Capuano5, Patrick M. Sexton1, Steven J. Charlton2, Jonathan A. Javitch3,4,6, Arthur Christopoulos1 & J Robert Lane1 Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects. This mechanism is usually inferred from pharmaco- logical data with the assumption that the confounding influences of observational (that is, assay dependent) and system (that is, cell background dependent) bias are excluded by experimental design and analysis. Here we reveal that ‘kinetic context’, as determined by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias. We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism. 1 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia. 2 Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham NG7 2UH, UK. 3 Departments of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. 4 Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
    [Show full text]